While HER2 overexpression is noted in more than 50% of DCIS, only 20–30% of IBC overexpress HER2 (45), suggesting a possible emergence of HER2-negative tumor cells due to immunoediting after elimination of HER2-positive cells. Here, ERBB2 is linked to ductal breast carcinoma in situ.